Member Info for MisterPositive

Interesting to note:

Exercise price of warrants that RF would have to pay to Genedrive is 10.86p as per previous RNS

Yes 1.5p is jus the nominal value of shares. You can ignore that.

Amazing Volume today..almost 18 times daily avg

Good to see Riverfort out now after selling their last tranch today on HIGH VOLUME day.

Agree. £100m MCap would be at very low end.

I see GDR gaining lot more traction. Need to stay with it. Genedrive could give you biggest ROI this year in my opinion.

Popeye....time for some Spinach mate 😁

Lot of folk running with their own strategy.

Wih FDA update so close, this could really take off towards +20p. They can raise funds then at 15p or higher.

Expect an even bigger push higher after that.

Lot of "Doom" merchants suddenly show up trying to get in cheaper....way too obvious.

We funded via Riverfort for another 4 months.

FDA partner funding talks in progress already. Incoming US partner could also pay upfront Cash for lets say 5% - 10% equity stake in GDR. Lot of options available especially after todays Transformational news on STROKE test recommendation by NICE. You can also have bigger Industry players looking to get in also as early investors in GDR.

They will have the option to raise funds may be in 3 months time in high DOUBLE DIGITS after further pending positive news and clear out Riverfort for good.

Just wait till FUND MANAGERS start taking positions both in the UK and USA.

FDA update should start the party here BIG TIME.

Yes nissangtr. Agree with you. We have seen many times GDR move at lightning speed with low number of shares about.

I remember when GDR rocketed from 10p to 80p in just over a week when Market piled in 2 yrs ago

Agree. Far too cheap.

Was 27.2p last year on 3 Apr 2023 (80% down).

With todays "Transformational" news on STROKE test recommendation by NICE is a MASSIVE endorsement for Genedrive to regain its GLORY.

BIG PHARMA would be watching further developments here for sure given STROKE test market is worth Multi-Billion $$$ worldwide.

Artemis (ARV) is significantly undervalued on any metric given its prime location and recent discoveries on some highly prospective ground next to proven discoveries.

In due course even 11.2p would look mega cheap.

Agree. Seemed like fake drop to fill the Buy order.

Looking forward to positive Updates next week due on Multiple fronts.

Bigeasy.

Very nicely summarised. Spot on. You nailed it.

I myself used to support Stock borrow / lending trading desk in my earlier career and know how these sharks work. Unfortunately management of Pharma / Biotech companies fall for their glittery deal structures. Rest of the game you know.

May be James Cheek (CEO) reads GDR chat board and finally got the true picture.

Some good posts. Just catching up here. Staying put here as this will come good. Been frustrating yes, but GDR could prove to be one of the best turnaround / recovery stock for 2024 regaining its past glory.

From last RNS, i get a feeling Management has realised now that RF finance deal was a bad choice and could soon be cancelling that and replace with a standard placing deal to get rid of current RF deal. Interesting to note that RF warrants Exercise price is upwards of +10p.

Even the slightest sniff of RF deal cancelled...and there will be major fireworks in share price rocket 🚀 upwards as market just want RF out.

Followed by RNS updates on NICE and FDA in USA. Then we would be back on track to massive price gains. Almost there now in my view.

London price was trading circa 40% below ASX price in Australia.

ASX closed at 2.10 cents on double the daily average traded volume.

London price should be around 1.20 - 1.25

Still trading at a discount to ASX price.

I expect ASX to continue rising especially after superb initial results from ARV 100% owned Mt Marie licence which confirm Spodumene lithium source and at par with same grades to next door Azure Minerals currently subject to A$1.76bn take over offer price.

Wont be surprised if this hit over +2p in coming days and still would be mega cheap.

Some bio-tech firms take years to develop a breakthrough, market disruptive product.

Genedrive....very apt name coz genes driven therapy and testing is the future.

BIG PHARMA know it and would swallow any small bio-tech with those intellectual rights to such products.

James Cheek had to deal with a lot since coming on board...fully focused on progressing product sales for AIHL test to establish a revenue stream. Stroke tests would be next with lot of progress already made.

Pharmacogenetics market expected to hit $40bn by 2033. Genedrive can capture a good chunk of that in Worldwide sales in coming years.

Price would be in multiple £££s...not pennies if you stay here in next 5-10 years. GeneDrive would be a different fish altogether.

IMHO. DYOR

Some great posts..Stephen, Jimi and Lionel.

We on the cusp of doing +100% plus on next positive news.

We could get back to back RNS on multiple fronts and this could do even 200%-300%.

Shorters know it and seem worried as we could get a big short squeeze knowing how fast this moves.

Https://finance.yahoo.com/news/pharmacogenomics-market-demand-hit-usd-123700000.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAADKSoPURMaVvp9acZldMePR7KReoHpCFT05p7BchPl4aHYiKqs9GxGxOTbIqa3zp57zDS44xI8y_pW8FEgtAEH8a6hDNmVpEXCazdIhxXEcHKMYI4XaDyV6MQuFlj3mLsSIUkGs0w2S9D0ApCx38slg9h9tckyzrc23Z2jMqI6Yh

Guy...not really. Think you got it wrong.

Product sale price will most likely be in local currency of the country.

E.g. you can buy same iphone in UK, Europe and USA but priced very differently.

"this level of li2o result is unparalleled in the region and is on par with the results achieved at the andover project of azure minerals ltd where they recorded a peak rock chip assay result of 4.87% li2o3 and have reported an exploration target of 100-240mt @ 1.00-1.5% li2o4 (azure minerals is currently subject to a takeover proposal via a joint bid from sociedad quimica y minera de chile sa (sqm) and han**** prospecting pty ltd)."

azure currently under a$1.76 billion buy out offer.

mt marie - looking better and better than expected. artemis sitting on something special. current mcap only a$30m ?

Guy

No pump n dump here sir. I am taking advantage of this low price to accumulate few more wherever i can to build a decent size position.

Cannot speak for others. Each to their own.

But can see fair few investors starting to take positions here for March updates on "Multiple" fronts. Could get back to back RNS.

52 week high....48.86 pence.

Adjusted for dilution, with positive news on different fronts, this can rocket to +40p in no time.

At only 5p this is defo a STRONG BUY in my books.

The Pharmacogenomics Market size is estimated at USD 8.67 billion in 2024, and is expected to reach USD 11.67 billion by 2029, growing at a CAGR of 6.12% during the forecast period (2024-2029).

Pharmacogenetic testing may be used to: Find out whether a certain medicine could be effective for you. Find out how much of the medicine you need. Predict whether you will have a serious side effect from a medicine.